Formulations using penetration enhancers (DMSO, liposomes, nanoparticle carriers) improve dermal delivery but produce negligible systemic absorption
For established keloids, other treatments remain the primary approach
(12, 13) Helping to regenerate vitamins C, E and A, all antioxidants or vitamins with antioxidant properties in their own right
19 (4), e0302209 (2024)
Kennedy, who has said he used peptides with "really good effect", has argued that restrictions on the compounds have pushed consumers toward an unregulated gray market
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
